{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:34:58Z","timestamp":1792096498088,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-04908-2","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:52:15Z","timestamp":1749196335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimal positioning of biomarkers according to ulcerative colitis activity"],"prefix":"10.1038","volume":"15","author":[{"given":"Natsuki","family":"Ishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Takebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Yamade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriya","family":"Iwaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Hamaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"4908_CR1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner, D. et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160, 1570\u20131583 (2021).","journal-title":"Gastroenterology"},{"key":"4908_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/gut.2008.170019","volume":"58","author":"D Foell","year":"2009","unstructured":"Foell, D., Wittkowski, H. & Roth, J. Monitoring disease activity by stool analyses: From occult blood to molecular markers of intestinal inflammation and damage. Gut 58, 859\u2013868 (2009).","journal-title":"Gut"},{"key":"4908_CR3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699\u2013710 (2013).","journal-title":"N. Engl. J. Med."},{"key":"4908_CR4","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands, B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381, 1201\u20131214 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4908_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.gastro.2022.12.007","volume":"164","author":"S Singh","year":"2023","unstructured":"Singh, S. et al. AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis. Gastroenterology 164, 344\u2013372 (2023).","journal-title":"Gastroenterology"},{"key":"4908_CR6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/ajg.2015.66","volume":"110","author":"S Takashima","year":"2015","unstructured":"Takashima, S. et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin versus fecal immunochemical test. Am. J. Gastroenterol. 110, 873\u2013880 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"4908_CR7","first-page":"313","volume":"37","author":"SP Ballou","year":"1992","unstructured":"Ballou, S. P. & Kushner, I. C-reactive protein and the acute phase response. Adv. Intern. Med. 37, 313\u2013336 (1992).","journal-title":"Adv. Intern. Med."},{"key":"4908_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/ecco-jcc\/jjw132","volume":"11","author":"S Shinzaki","year":"2017","unstructured":"Shinzaki, S. et al. Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. J. Crohns Colitis 11, 84\u201391 (2017).","journal-title":"J. Crohns Colitis"},{"key":"4908_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1097\/MIB.0000000000000062","volume":"20","author":"Y Arai","year":"2014","unstructured":"Arai, Y. et al. Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis. Inflamm. Bowel Dis. 20, 1208\u20131216 (2014).","journal-title":"Inflamm. Bowel Dis."},{"key":"4908_CR10","doi-asserted-by":"publisher","first-page":"9898","DOI":"10.1038\/s41598-023-37145-6","volume":"13","author":"S-I Hagiwara","year":"2023","unstructured":"Hagiwara, S.-I. et al. Utility of a rapid assay for prostaglandin E-major urinary metabolite as a biomarker in pediatric ulcerative colitis. Sci. Rep. 13, 9898 (2023).","journal-title":"Sci. Rep."},{"key":"4908_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro, F. et al. Third European Evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J. Crohns Colitis 11, 649\u2013670 (2017).","journal-title":"J. Crohns Colitis"},{"key":"4908_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12876-020-01256-5","volume":"20","author":"N Ishida","year":"2020","unstructured":"Ishida, N. et al. Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis. BMC Gastroenterol. 20, 114 (2020).","journal-title":"BMC Gastroenterol."},{"key":"4908_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/jgh.15782","volume":"37","author":"T Sakurai","year":"2022","unstructured":"Sakurai, T. et al. Prostaglandin E-major urinary metabolite diagnoses mucosal healing in patients with ulcerative colitis in remission phase. J. Gastroenterol. Hepatol. 37, 847\u2013854 (2022).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"4908_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ecco-jcc\/jjad130","volume":"18","author":"S Schreiber","year":"2024","unstructured":"Schreiber, S. et al. Defining comprehensive disease control for use as a treatment target for ulcerative colitis in clinical practice: international Delphi Consensus Recommendations. J. Crohns Colitis 18, 91\u2013105 (2024).","journal-title":"J. Crohns Colitis"},{"key":"4908_CR15","doi-asserted-by":"publisher","first-page":"11086","DOI":"10.1038\/s41598-021-90441-x","volume":"11","author":"E Yasutomi","year":"2021","unstructured":"Yasutomi, E. et al. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. Sci. Rep. 11, 11086 (2021).","journal-title":"Sci. Rep."},{"key":"4908_CR16","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/ibd\/izac230","volume":"29","author":"T Shimoyama","year":"2023","unstructured":"Shimoyama, T., Yamamoto, T., Yoshiyama, S., Nishikawa, R. & Umegae, S. Leucine-rich alpha-2 glycoprotein is a reliable serum biomarker for evaluating clinical and endoscopic disease activity in inflammatory bowel disease. Inflamm. Bowel Dis. 29, 1399\u20131408 (2023).","journal-title":"Inflamm. Bowel Dis."},{"key":"4908_CR17","doi-asserted-by":"publisher","first-page":"12431","DOI":"10.1038\/s41598-021-90558-z","volume":"11","author":"N Ishida","year":"2021","unstructured":"Ishida, N. et al. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis. Sci. Rep. 11, 12431 (2021).","journal-title":"Sci. Rep."},{"key":"4908_CR18","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.cgh.2006.07.015","volume":"4","author":"JC Johnson","year":"2006","unstructured":"Johnson, J. C. et al. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin. Gastroenterol. Hepatol. 4, 1358\u20131365 (2006).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"4908_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1940-6207.CAPR-13-0040","volume":"6","author":"S Kim","year":"2013","unstructured":"Kim, S., Taylor, J. A., Milne, G. L. & Sandler, D. P. Association between urinary prostaglandin E2 metabolite and breast cancer risk: A prospective, case-cohort study of postmenopausal women. Cancer Prev. Res. (Phila.) 6, 511\u2013518 (2013).","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"4908_CR20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/cancers11060768","volume":"11","author":"H Kawamoto","year":"2019","unstructured":"Kawamoto, H. et al. Prostaglandin E-major urinary metabolite (PGE-MUM) as a tumor marker for lung adenocarcinoma. Cancers (Basel) 11, 768 (2019).","journal-title":"Cancers (Basel)"},{"key":"4908_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jcla.21640","volume":"28","author":"I Okayasu","year":"2014","unstructured":"Okayasu, I. et al. Significant increase of prostaglandin E-major urinary metabolite in male smokers: A screening study of age and gender differences using a simple radioimmunoassay. J. Clin. Lab. Anal. 28, 32\u201341 (2014).","journal-title":"J. Clin. Lab. Anal."},{"key":"4908_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.rmed.2016.11.017","volume":"122","author":"T Horikiri","year":"2017","unstructured":"Horikiri, T. et al. Increased levels of prostaglandin E-major urinary metabolite (PGE-MUM) in chronic fibrosing interstitial pneumonia. Respir. Med. 122, 43\u201350 (2017).","journal-title":"Respir. Med."},{"key":"4908_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","volume":"298","author":"D Rachmilewitz","year":"1989","unstructured":"Rachmilewitz, D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 298, 82\u201386 (1989).","journal-title":"BMJ"},{"key":"4908_CR24","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder, K. W., Tremaine, W. J. & Ilstrup, D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317, 1625\u20131629 (1987).","journal-title":"N. Engl. J. Med."},{"key":"4908_CR25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/gut.47.3.404","volume":"47","author":"K Geboes","year":"2000","unstructured":"Geboes, K. et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47, 404\u2013409 (2000).","journal-title":"Gut"},{"key":"4908_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transplant."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04908-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04908-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04908-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:52:16Z","timestamp":1749196336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04908-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4908"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04908-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Ethics Committee of Hamamatsu University School of Medicine (number 20-178). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19916"}}